DISCLAIMERThe information and materials accessed through or made available for use on any of our Sites, including, any information about diseases, conditions, treatments, or medicines, are for informational purposes only. The Content is not intended to be and is not a substitute for professional medical advice, diagnosis, or treatment, and your participation on our Sites does not create a healthcare professional-patient relationship. You should consult a doctor or other qualified health care professional regarding any questions you have about your health or before making any decisions related to your health or wellness. Call your doctor or 911 immediately if you think you may have a medical emergency.
|You are receiving this because you have an account on www.oneGRAVESvoice.com|
|To unsubscribe from these emails, click here|
Trusted Resources: News & Meetings
Latest announcements and gatherings
Horizon Therapeutics plc today announced its third-quarter 2019 financial results and raised the midpoint of its full-year 2019 adjusted EBITDA guidance.
“Our third-quarter performance underscores the strength of our commercial and R&D organizations,” said Timothy Walbert, chairman, president and chief executive officer, Horizon. “We generated record quarterly net sales in our orphan and rheumatology segment – including a record quarter for net sales of KRYSTEXXA, our medicine for uncontrolled gout – and the U.S. FDA also granted Priority Review of our BLA for teprotumumab, our biologic candidate for the treatment of active thyroid eye disease. We made great progress on all fronts during the quarter, including our market education activities related to teprotumumab, and remain excited about the prospect of being able to address the significant unmet need for patients living with active thyroid eye disease.”
People & PlacesVictor Maurice Elner, MD, PhDVictor Maurice Elner is a Professor of o...
People & PlacesEric Hink, MDEric Hink is Associate Professor of opht...
Evidence & EducationDoes Treatment of Graves’ Disease Modify The Long-Term Course of Graves’ Orbitopathy?Introduction: Graves’ orbitopathy (GO...
Evidence & EducationTEPEZZA (teprotumumab-trbw)- Frequently Asked Questions1. What is TEPEZZA? TEPEZZA is the firs...
Evidence & EducationSmoking Induces Overexpression of Immediate Early Genes in Active Graves’ OphthalmopathyBackground: Cigarette smoking is a risk...
Evidence & EducationUpdate on Graves’ Disease: Advances in Treatment of Mild, Moderate and Severe Thyroid Eye DiseasePurpose of Review: To report the most r...
Evidence & EducationOftalmopatía de Graves u Orbitopatía de Graves¿Qué Es La Oftalmopatía De Graves? L...
send a message
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.